Glucagon‐like peptide‐1 therapy in people with obesity restores natural killer cell metabolism and effector function
Authors' conclusion
The restoration, by GLP-1 therapy, of NK cell functionality in PWO may be contributing to the overall benefits being seen with this class of medication.
Study context
- Population
- People with obesity (PWO) receiving once weekly GLP-1 therapy (semaglutide)
- Participants
- 20 people
- Comparison
- Natural killer (NK) cell function and metabolism before vs after GLP-1 therapy
- Outcome
- NK cell function and metabolism
- Follow-up
- 6 months
Methodological detailsprospective cohort, 6 months of once weekly semaglutide, Multicolor flow cytometry, enzyme-linked immunosorbent assays and cytotoxicity assays
- Prospective cohort
- 6 months of once weekly semaglutide
- Multicolor flow cytometry, enzyme-linked immunosorbent assays and cytotoxicity assays
Main finding
As reported in the abstract
6 months
- Improved NK cell function (cytotoxicity and interferon-γ/granzyme B production) with GLP-1 therapy
- Increases in a CD98-mTOR-glycolysis metabolic axis, critical for NK cell cytokine production
- Improvements in NK cell function appear independent of weight loss
Original publication
Glucagon‐like peptide‐1 therapy in people with obesity restores natural killer cell metabolism and effector function. Obesity (Silver Spring). Published 9 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →